BACKGROUND AND OBJECTIVES: Considerable progress has been made in the treatment
of acute myeloid leukemia (AML); however, current therapeutic results are still unsatisfactory …

The improved survival of patients with AML over the last 20–30 years can be attributed both
to advances in cytotoxic therapy and in supportive care and up to 25% of responders may be …

Two major prognostic factors for outcomes with acute myeloid leukemia (AML) therapy
center on cytogenetic/molecular markers and patient age. With the paucity of novel agents …

In the United States, only a small minority of patients with cancer are enrolled in clinical
studies. 1 It has been estimated that only about 5% to 10% of adults with acute myeloid …

The diagnosis of AML rests on demonstration that the marrow contains> 20% blasts of
myeloid lineage. The overarching therapeutic decision is whether the patient should receive …

This book, written by a team of leading experts, provides a comprehensive overview of acute
myeloid leukemia (AML), the most frequent acute leukemia in adults. The opening chapters …

Relapse remains common in adults with acute myeloid leukemia (AML), with long-term
disease-free survival estimated at 30–40% for patients 60 years or younger treated with …

The curability of acute myeloid leukaemia (AML) in a fraction of adult patients was
demonstrated a long time ago. Currently, the probability of cure is consistently above fifty per …

Despite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients
with relapsed disease is extremely poor. The median overall survival for patients with …

Acute myeloid leukemia (AML) includes all acute leukemias characterized by cells of other
than lymphoid origin. AML subgroups with special clinical features have been defined by …